A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.

• Phase: Phase 3

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Receiving stable maintenance peritoneal dialysis

• Peritoneal dialysis patients with hyperphosphatemia

Exclusion Criteria:

• Patients having history of a pronounced brain / cardiovascular disorder

• Patients having severe gastrointestinal disorders

• Patients having severe hepatic disorders